Abstract
With the economy sputtering toward recovery, federal outlays shriveling and the political scene in upheaval, the US biotech policy picture is more than a little blurred. Jeffrey L. Fox reports.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have